<DOC>
	<DOC>NCT02961270</DOC>
	<brief_summary>This study aims to evaluate the efficacy of icotinib, a first generation EGFR TKI, in non-small cell lung cancer patients harboring uncommon EGFR mutation</brief_summary>
	<brief_title>Icotinib in Non-small Cell Lung Cancer Patients With Uncommon EGFR Mutation</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<criteria>Patients with stage IIIB/IV nonsmall cell lung cancer Patients with uncommon epidermal growth factor receptor (EGFR) mutation Targetedtherapynaive patients Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2 Evaluable target lesions according to RECIST 1.1 for tumour response assessment Wildtype EGFR Positive 19 del and/or 21 L858R mutation Previous treatment with EGFR TKIs such as gefitinib, erlotinib, and afatinib Patients who have documented history of interstitial lung disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>